NCT04836728View on ClinicalTrials.gov

Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2026

Conditions
Non-small Cell Lung Cancer MetastaticFirst-line Treatment
Interventions
BIOLOGICAL

CIK cells injection

CIK cells, more than 1x10\^10 (10 billion ), intravenous infusion, d14, Q3W.

DRUG

Sintilimab Injection

200 mg, intravenous infusion, d1, every 3 weeks

DRUG

Pemetrexed

500 mg/m\^2, intravenous infusion, d1, every 3 weeks

DRUG

Albumin paclitaxel

260 mg/m\^2, intravenous infusion, d1, every 3 weeks

DRUG

Carboplatin

AUC 5, intravenous infusion, d1, every 3 weeks

Trial Locations (1)

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER